Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group

• Complementary product portfolio and broad footprint of production sites in Europe
• Strengthening the market position as a full-service provider for the pharma and biotech industry
• Strategic reset of Moulded Glass business

Düsseldorf, December 11, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has successfully completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group announced in May 2024. The closing was preceded by the fulfillment of customary closing conditions. Bormioli Pharma has a portfolio of pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems that is complementary to Gerresheimer. With this acquisition, Gerresheimer strengthens its European footprint with additional production sites and underpins its market position as a leading full-service provider and global partner for the pharma and biotech industries. Gerresheimer expects the acquisition to be accretive to the Group's Adj. EBITDA margin and Adj. EPS from the first year onwards through synergies. On February 26, 2025, Gerresheimer will publish a new guidance for the combined company together with the results for the financial year 2024.

"Following the successful completion of the acquisition, we can now focus on the integration of Bormioli Pharma into the Gerresheimer Group," explains Dietmar Siemssen, CEO of Gerresheimer AG. "We are convinced that our customers will benefit from the expansion of the product portfolio and new, integrated systems and solutions."

Complementary, attractive product portfolio

In 2023, Bormioli Pharma generated sales of around EUR 371 million and an Adj. EBITDA margin of around 22%. The company manufactures pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems. In the plastics segment, Bormioli Pharma is one of the leading suppliers of pharmaceutical plastic systems and solutions. In the glass segment, Bormioli Pharma has an attractive portfolio for parenteral and other pharmaceutical primary packaging.

Strategic reset of Moulded Glass business

The acquisition creates a new, strong Moulded Glass unit with a diversified product portfolio for the pharmaceutical, cosmetics, food and beverage industries. This globally active unit offers new options for a strategic reset for the best growth prospects and competitiveness, which will be evaluated in the coming months.

New guidance for combined company in February 2025

Bormioli Pharma will become part of the Gerresheimer Group and will be fully consolidated retroactively as of December 1, 2024, the start of Gerresheimer's new financial year 2025. Therefore, on February 26, 2025, together with the results for the financial year 2024, Gerresheimer will publish a new guidance for 2025 and a new mid-term guidance for the combined company.     

About Bormioli Pharma

Established in 1825, Bormioli Pharma is a leading pharma primary packaging manufacturer serving the industry with complete solutions, including glass and plastic bottles, plastic and aluminum closures and accessories. Bormioli Pharma's products are designed and manufactured to drive innovation and deliver effective solutions to the growing challenges of sustainability. Bormioli Pharma has become part of the Gerresheimer Group in December 2024, an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. Gerresheimer operates over 40 production sites in 16 countries in Europe, America and Asia and currently employs around 13,400 people.

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets.  The Group generated revenues of around €2bn in 2023 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).  

Contact Gerresheimer AG